David M. Charytan

David M. Charytan

Auto-generated profile, based on publicly available information

David M. Charytan

Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
VPVlado Perkovic
Vlado Perkovic
MJMeg J. Jardine
Meg J. Jardine
Bruce NealBruce Neal
Bruce Neal
SBSeverine Bompoint
Severine Bompoint
HHHiddo J.L. Heerspink
Hiddo J.L. Heerspink
KMKenneth W. Mahaffey
Kenneth W. Mahaffey
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.)

15 June 2003 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
MZMichael Zeisberg
Michael Zeisberg
JHJun-Ichi Hanai
Jun-Ichi Hanai
HSHikaru Sugimoto
Hikaru Sugimoto
TMTadanori Mammoto
Tadanori Mammoto
DCDavid Charytan
David Charytan
RKRaghu Kalluri
Raghu Kalluri

1 November 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
BNBrendon L Neuen
Brendon L Neuen
TYTamara Young
Tamara Young
HHHiddo J L Heerspink
Hiddo J L Heerspink
Bruce NealBruce Neal
Bruce Neal
VPVlado Perkovic
Vlado Perkovic
MJMeg J Jardine
Meg J Jardine

1 September 2011 in Kidney International
Verified
Journal Article
Closed access
CHCharles A. Herzog
Charles A. Herzog
RARichard W. Asinger
Richard W. Asinger
ABAlan K. Berger
Alan K. Berger
DCDavid M. Charytan
David M. Charytan
JDJavier Díez
Javier Díez
EREberhard Ritz
Eberhard Ritz

1 October 2019 in JACC
Verified
Journal Article
Open access
MSMark J. Sarnak
Mark J. Sarnak
KAKerstin Amann
Kerstin Amann
SBSripal Bangalore
Sripal Bangalore
JCJoão L. Cavalcante
João L. Cavalcante
DCDavid M. Charytan
David M. Charytan
AZAlexander Zarbock
Alexander Zarbock
Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research.

1 July 2020 in eClinicalMedicine
Verified
Journal Article
Open access
ARAmy V. Rapkiewicz
Amy V. Rapkiewicz
XMXingchen Mai
Xingchen Mai
SCSteven E. Carsons
Steven E. Carsons
SPStefania Pittaluga
Stefania Pittaluga
DKDavid E. Kleiner
David E. Kleiner
HRHarmony R. Reynolds
Harmony R. Reynolds
There is increasing recognition of a prothrombotic state in COVID-19. Post-mortem examination can provide important mechanistic insights. We present a COVID-19 autopsy series including findings in lungs, heart, kidneys, liver, and bone, from a New York academic medical center. In seven patients (four female), regardless of anticoagulation status, all autopsies demonstrated platelet-rich thrombi in the pulmonary, hepatic, renal, and cardiac microvasculature. Megakaryocytes were seen in higher than usual numbers in the lungs and heart. Two cases had thrombi in the large pulmonary arteries, where casts conformed to the anatomic location. Thrombi in the IVC were not found, but the deep leg veins were not dissected. Two cases had cardiac venous thrombosis with one case exhibiting septal myocardial infarction associated with intramyocardial venous thrombosis, without atherosclerosis. One case had focal acute lymphocyte-predominant inflammation in the myocardium with no virions found in cardiomyocytes. Otherwise, cardiac histopathological changes were limited to minimal epicardial inflammation (n = 1), early ischemic injury (n = 3), and mural fibrin thrombi (n = 2). Platelet-rich peri‑tubular fibrin microthrombi were a prominent renal feature. Acute tubular necrosis, and red blood cell and granular casts were seen in multiple cases. Significant glomerular pathology was notably absent. Numerous platelet-fibrin microthrombi were identified in hepatic sinusoids. All lungs exhibited diffuse alveolar damage (DAD) with a spectrum of exudative and proliferative phases including hyaline membranes, and pneumocyte hyperplasia, with viral inclusions in epithelial cells and macrophages. Three cases had superimposed acute bronchopneumonia, focally necrotizing. In this series of seven COVID-19 autopsies, thrombosis was a prominent feature in multiple organs, in some cases despite full anticoagulation and regardless of timing of the disease course, suggesting that thrombosis plays a role very early in the disease process. The finding of megakaryocytes and platelet-rich thrombi in the lungs, heart and kidneys suggests a role in thrombosis. None.